Expertise in
64
conditions

Dr. Ian C. Anderson

Hematology Oncology
3555 Round Barn Circle, Suite A, 
Santa Rosa, CA 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
64
conditions
3555 Round Barn Circle, Suite A, 
Santa Rosa, CA 

Overview

Ian Anderson is a Hematologist Oncology provider practicing medicine in Santa Rosa, California.

Dr. Anderson is highly rated in 64 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Adenocarcinoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 25 clinical trials. Dr. Anderson is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Providence Santa Rosa Memorial Hospital
Petaluma Valley Hospital
Healdsburg Hospital
Sonoma Valley Hospital
Adventist Health Mendocino Coast

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 12 Less Insurance Carriers -

Locations

3555 Round Barn Circle, Suite A, Santa Rosa, CA 95403

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: May 27, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 15, 2026
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation
Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation
Enrollment Status: Approved_for_marketing
Publish Date: August 26, 2025
Intervention Type: Drug
A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Enrollment Status: Terminated
Publish Date: April 24, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
View 7 Less Clinical Trials

10 Total Publications

We need transparency standards for social media research that involves companies.
We need transparency standards for social media research that involves companies.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 10, 2025
Similar Doctors
Expertise in
28
conditions
Dr. Wei Z. Ai
Hematology Oncology
Expertise in
28
conditions
Dr. Wei Z. Ai
Hematology Oncology
Referral may be required

Cutaneous Lymphoma Clinic

1701 Divisadero St., Fourth Floor, 
San Francisco, CA 
 (47.7 miles away)
415-353-7800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Wei Ai is a blood cancer specialist who cares for adults with conditions such as Hodgkin's lymphoma and non-Hodgkin's lymphoma, including cutaneous lymphomas, which primarily involve the skin. She also sees patients needing blood and bone marrow transplantation. In her research, Ai focuses on novel approaches to lymphoma treatment, especially targeted agents for T-cell lymphomas. Her studies often lead to clinical trials of new therapies that target cancer at the molecular level. Ai earned a doctoral degree in microbiology and immunology as well as her medical degree from Stanford University School of Medicine. She completed a residency in internal medicine at UCSF, followed by fellowship training in medical oncology at Stanford. Dr. Ai is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Ai is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Ai is currently accepting new patients.

Expertise in
51
conditions
Dr. Leroy W. Keiser
Hematology Oncology | Hematology
Expertise in
51
conditions
Dr. Leroy W. Keiser
Hematology Oncology | Hematology
Referral may be required
3555 Round Barn Circle, Suite A, 
Santa Rosa, CA 
 (2.7 miles away)
707-528-1050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leroy Keiser is a Hematologist Oncology specialist and a Hematologist practicing medicine in Santa Rosa, California. Dr. Keiser is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Polycythemia Vera, and Richter Syndrome. Dr. Keiser is currently accepting new patients.

Expertise in
48
conditions
Dr. Jarrod P. Holmes
Hematology Oncology | Hematology
Expertise in
48
conditions
Dr. Jarrod P. Holmes
Hematology Oncology | Hematology
Referral may be required
3555 Round Barn Circle, Suite A, 
Santa Rosa, CA 
 (2.7 miles away)
707-528-1050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jarrod Holmes is a Hematologist Oncology specialist and a Hematologist practicing medicine in Santa Rosa, California. Dr. Holmes is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), Breast Cancer, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Holmes is currently accepting new patients.

Frequently Asked Questions about Dr. Ian C. Anderson

How do I make an appointment with Dr. Ian C. Anderson?

You can book an appointment with Dr. Ian C. Anderson by calling their office at 707-528-1050. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ian C. Anderson a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ian C. Anderson is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ian C. Anderson specialize in?

While Dr. Ian C. Anderson is a Hematology Oncology, they have specific expertise in Lung Cancer, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Ian C. Anderson participate in research or clinical trials?

Yes. Dr. Ian C. Anderson has published 10 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Ian C. Anderson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ian C. Anderson accept my insurance?

Dr. Ian C. Anderson accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 707-528-1050 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Anderson's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 53 Advanced Conditions
    View All 134 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile